Kedrion Biopharma and Kamada are forging ahead with the development of a new Anti-COVID Immunoglobulin therapy derived from the plasma of convalescent patients.
Choose your country
Kedrion Biopharma and Kamada are forging ahead with the development of a new Anti-COVID Immunoglobulin therapy derived from the plasma of convalescent patients.
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.